Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

Fig. 2

Plasma 6α-OH-paclitaxel/paclitaxel AUC ratio as a function of pictilisib dose. Patients with evaluable 6α-OH-paclitaxel and paclitaxel PK after multiple doses of paclitaxel and pictilisib were pooled across all paclitaxel treatment arms (parts 1 and 2, n = 49). Black lines represent the median ratio for each dose level, and dots represent individual subject ratios. PK Pharmacokinetics

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us